Argon pharmacokinetics : a solubility measurement technique
The noble gas argon has demonstrated biological activity that may prove useful as a medical intervention. Pharmacokinetics, the disposition of the drug molecule in the body through time, is fundamental necessary knowledge to drug discovery, development and even post-marketing. The fundamental measurement in pharmacokinetic studies is blood concentration of the molecule (and its metabolites) of interest. While a physiologically based model of argon pharmacokinetics has appeared in the literature, no experimental data have been published. Thus, argon pharmaceutical development requires measurement of argon solubility in blood. This paper reports on the development of a technique based on mass spectrometry for measuring argon solubility in liquids, including blood, to be further employed in pharmacokinetics testing of argon. Based on a prototype, results are reported from sensitivity experiments using ambient air, water and rabbit blood. The key takeaway is that the system was sensitive to argon during all of the testing. We believe the technique and prototype of the quadrupole mass spectrometer gas analyzer will be capable of inferring argon pharmacokinetics through the analysis of blood samples.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Medical gas research - 13(2023), 4 vom: 14. Okt., Seite 208-211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lemaire, Joël [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
059QF0KO0R |
|---|
| Anmerkungen: |
Date Completed 21.04.2023 Date Revised 31.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4103/2045-9912.351106 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35580932X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35580932X | ||
| 003 | DE-627 | ||
| 005 | 20231226210251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/2045-9912.351106 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM35580932X | ||
| 035 | |a (NLM)37077120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lemaire, Joël |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Argon pharmacokinetics |b a solubility measurement technique |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2023 | ||
| 500 | |a Date Revised 31.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The noble gas argon has demonstrated biological activity that may prove useful as a medical intervention. Pharmacokinetics, the disposition of the drug molecule in the body through time, is fundamental necessary knowledge to drug discovery, development and even post-marketing. The fundamental measurement in pharmacokinetic studies is blood concentration of the molecule (and its metabolites) of interest. While a physiologically based model of argon pharmacokinetics has appeared in the literature, no experimental data have been published. Thus, argon pharmaceutical development requires measurement of argon solubility in blood. This paper reports on the development of a technique based on mass spectrometry for measuring argon solubility in liquids, including blood, to be further employed in pharmacokinetics testing of argon. Based on a prototype, results are reported from sensitivity experiments using ambient air, water and rabbit blood. The key takeaway is that the system was sensitive to argon during all of the testing. We believe the technique and prototype of the quadrupole mass spectrometer gas analyzer will be capable of inferring argon pharmacokinetics through the analysis of blood samples | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a argon | |
| 650 | 4 | |a blood | |
| 650 | 4 | |a gas solubility | |
| 650 | 4 | |a headspace | |
| 650 | 4 | |a noble gas | |
| 650 | 4 | |a partition coefficient | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a quadrupole mass spectrometry | |
| 650 | 7 | |a Argon |2 NLM | |
| 650 | 7 | |a 67XQY1V3KH |2 NLM | |
| 650 | 7 | |a Water |2 NLM | |
| 650 | 7 | |a 059QF0KO0R |2 NLM | |
| 700 | 1 | |a Heninger, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Louarn, Essyllt |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Ira |e verfasserin |4 aut | |
| 700 | 1 | |a Tissier, Renaud |e verfasserin |4 aut | |
| 700 | 1 | |a Chalopin, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Farjot, Géraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Milet, Aude |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical gas research |d 2012 |g 13(2023), 4 vom: 14. Okt., Seite 208-211 |w (DE-627)NLM216076978 |x 2045-9912 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:4 |g day:14 |g month:10 |g pages:208-211 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/2045-9912.351106 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 4 |b 14 |c 10 |h 208-211 | ||